Novo to acquire heart failure drug in $1B deal for Cardior

25 Mar 2024
www.biopharmadive.com
Phase 2AcquisitionClinical ResultOligonucleotidePhase 1
Dive Brief:
Novo Nordisk will pay as much as $1 billion to acquire RNA drug developer Cardior and its experimental treatment for heart failure, the companies announced Monday.
Cardior’s treatment, dubbed CDR132L, is currently being tested in a mid-stage study involving 280 people with heart failure who previously experienced a heart attack. Results are expected by September, according to a U.S. clinical trial database.
In addition to that study, Novo said it plans to start another Phase 2 trial in heart failure patients whose heart muscle has become thick and stiff, also known as cardiac hypertrophy. Novo, which will pay an undisclosed upfront payment to Cardior per deal terms, expects the acquisition to close in the second quarter.
Dive Insight:
Historically, Novo hasn’t been the most active biotechnology company acquirer. But that’s changed somewhat over the past several years, as it’s invested in both RNA technology as well as in expanding its pipeline of drugs for cardiometabolic conditions.
The latter investment has coincided with a boom in sales of Novo’s diabetes and obesity medicines Ozempic and Wegovy, helping make Novo the second most valuable pharmaceutical company in the world. Within the obesity field, the company has struck deals for Inversago Pharma, Embark Biotech and EraCal Therapeutics.
With Cardior, meanwhile, Novo adds a heart disease treatment a company executive described as potentially “first-in-class.” An oligonucleotide, the drug is designed to block a specific kind of microRNA and help restore normal heart muscle cell function.
Phase 1b trial results were published in the European Heart Journal in January 2021 and showed that Cardior’s drug was well tolerated among the 28 treated study participants. The first patient in Cardior’s ongoing Phase 2 study was dosed in January 2022.
In addition to CDR132L, Cardior has two other disclosed drug programs in preclinical and discovery stages, respectively.
'
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.